https://scholars.lib.ntu.edu.tw/handle/123456789/634421
標題: | Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial | 作者: | Platzbecker, Uwe Della Porta, Matteo Giovanni Santini, Valeria Zeidan, Amer M Komrokji, Rami S Shortt, Jake Valcarcel, David Jonasova, Anna Dimicoli-Salazar, Sophie Tiong, Ing Soo CHIEN-CHIN LIN Li, Jiahui Zhang, Jennie Giuseppi, Ana Carolina Kreitz, Sandra Pozharskaya, Veronika Keeperman, Karen L Rose, Shelonitda Shetty, Jeevan K Hayati, Sheida Vodala, Sadanand Prebet, Thomas Degulys, Andrius Paolini, Stefania Cluzeau, Thomas Fenaux, Pierre Garcia-Manero, Guillermo |
公開日期: | 29-七月-2023 | 卷: | 402 | 期: | 10399 | 來源出版物: | Lancet (London, England) | 摘要: | Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk myelodysplastic syndromes but responses are limited and transient. Luspatercept promotes late-stage erythroid maturation and has shown durable clinical efficacy in patients with lower-risk myelodysplastic syndromes. In this study, we report the results of a prespecified interim analysis of luspatercept versus epoetin alfa for the treatment of anaemia due to lower-risk myelodysplastic syndromes in the phase 3 COMMANDS trial. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634421 | ISSN: | 01406736 | DOI: | 10.1016/S0140-6736(23)00874-7 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。